From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

EnSilica – full-year results argue “from both a financial and operational perspective… remains well positioned”. Er, does it?!…

By Steve Moore | Tuesday 5 November 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


With its results scheduled for today, I recently suggested why EnSilica (ENSI) may be ‘pleased to announce’ a new debt facility. Describing itself as “a leading chip maker of mixed signal Application Specific Integrated Circuits”, the company today headlines the announcement of the results for its year ended 31st May 2024 with “Ongoing contract momentum underpins significant demand for EnSilica's services. New contracts signed with a lifetime expected value of $65m post year end”. So why currently an approaching 7% lower share price response to back below 50p?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Friday »

Bearcast

Tom Winnifrith Bearcast: dash for trash

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

 

PICH

Pitch Pit – this stinks

Time left: 14:45:01